Maynard Um
-
-
-
-
-
-
-
TD Cowen Downgrades Jasper Therapeutics (JSPR) to Hold, 'now at a critical juncture'
-
-
-
-
-
-
-
Jasper Therapeutics reports positive briquilimab data for urticaria treatment
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) PT Lowered to $7 at BTIG
-
-
-
-
-
-
-
BMO Capital Downgrades Jasper Therapeutics (JSPR) to Market Perform
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) reports mixed results from urticaria drug trial
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Jasper Therapeutics (JSPR)
-
-
-
-
-
-
-
Stifel on Celldex (CLDX) and Third Harmonic Bio (THRD): 'we continue to like the prospects of CLDX and THRD as both first-in-class and an oral pure-play'
-
443,920 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

